https://solvonis.com/ https://solvonis.com/research-and-development/svn-001 https://solvonis.com/therapeutic-focus https://solvonis.com/research-and-development/pipeline https://solvonis.com/research-and-development/svn-002 https://solvonis.com/research-and-development/svn-ai-enabled-discovery-programme https://solvonis.com/research-and-development/svn-114 https://solvonis.com/research-and-development/svn-015 https://solvonis.com/about https://solvonis.com/contact https://solvonis.com/investor-relations/share-price-information https://solvonis.com/investor-relations/rns-announcements https://solvonis.com/investor-relations/financial-reports https://solvonis.com/investor-relations/shareholder-circulars https://solvonis.com/investor-relations/share-capital-information https://solvonis.com/investor-relations/advisors https://solvonis.com/investor-relations/analyst-coverage https://solvonis.com/investor-relations/corporate-presentation https://solvonis.com/contact/success https://solvonis.com/contact/success-newsletter https://solvonis.com/privacy-policy https://solvonis.com/news https://solvonis.com/news/solvonis-granted-u.s.-patent-from-ptsd-discovery-programme https://solvonis.com/news/svn-114-selected-as-the-lead-candidate-for-ptsd-discovery-programme https://solvonis.com/news/expansion-of-svn-015-into-depression-following-positive-preclinical-data https://solvonis.com/news/u.s.-patent-allowance-received-for-ptsd-discovery-programme https://solvonis.com/news/research-and-development-update-%E2%80%93-q4-2025 https://solvonis.com/news/svn-015-accepted-into-us-nida-funded-addiction-treatment-discovery-program-for-methamphetamine-and-cocaine-addiction https://solvonis.com/news/solvonis-appoints-global-biopharma-leader-paul-carter-as-non-executive-director-to-support-next-phase-of-strategic-growth https://solvonis.com/news/raises-1-25-million-to-accelerate-programmes-in-high-burden-cns-disorders https://solvonis.com/news/svn-sdn-14-ptsd-positive-pre-clinical-results https://solvonis.com/news/1-0-million-subscription-by-major-shareholders-to-accelerate-ai-drug-discovery-programme https://solvonis.com/news/initiation-of-research-coverage-by-singer-capital-markets https://solvonis.com/news/allowance-of-u-s-patent-covering-ai-supported-cns-discovery-programme-compounds https://solvonis.com/news/initiation-of-artificial-intelligence-supported-cns-drug-discovery-programme https://solvonis.com/news/completion-of-the-acquisition-of-awakn-life-sciences-corp https://solvonis.com/news/statement-on-the-appointment-dr-renata-crome-non-executive-director